A phase I clinical and pharmacokinetic study of the camptothecin glycoconjugate, BAY 38-3441, as a daily infusion in patients with advanced solid tumors.

BACKGROUND The aim of this study was to define the maximum tolerated dose (MTD), dose-limiting toxicity (DLT) and pharmacokinetics of the camptothecin glycoconjugate BAY 38-3441, administered as an infusion for 30 min on two separate schedules every 3 weeks. PATIENTS AND METHODS A total of 81 patients with advanced solid tumors were treated with BAY 38-3441 either at doses of 20, 40, 67, 100, 140, 210, 315, 470 and 600 mg/m2/day for 1 day every 3 weeks (single-dose schedule), or at doses of 126, 189, 246, 320 and 416 mg/m2/day once daily for three consecutive days every 3 weeks (3-day schedule). Plasma sampling was performed to characterize the pharmacokinetics of BAY 38-3441 and camptothecin with these schedules. RESULTS DLTs included renal toxicity, granulocytopenia and thrombocytopenia on the single-day schedule at doses > or = 470 mg/m2/day, and diarrhea and thrombocytopenia on the 3-day schedule at doses > or = 320 mg/m2/day. Other non-DLTs were gastrointestinal, dermatological and hematological. Pharmacokinetics of BAY 38-3441 and camptothecin appear to be dose-dependent, but not linear. CONCLUSIONS Renal toxicity was dose-limiting for BAY 38-3441 using 30-min infusions on the single-dose schedule. Dose escalation to 470 mg/m2/day is feasible using a 2-h infusion. However, because of the superior safety profile, we recommend the 3-day schedule for BAY 38-3441 at a dose of 320 mg/m2/day as 30-min infusions for further phase II studies.

[1]  Kensuke Matsumoto,et al.  Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice , 2004, Cancer Chemotherapy and Pharmacology.

[2]  P. Pantazis,et al.  The camptothecins : from discovery to the patient , 1996 .

[3]  I. Szumiel,et al.  Discrepancy between the initial DNA damage and cell survival after camptothecin treatment in two murine lymphoma L5178Y sublines , 1996, Cell biochemistry and function.

[4]  B. Giovanella,et al.  Pharmacokinetics of Camptothecins Administered Orally a , 1996, Annals of the New York Academy of Sciences.

[5]  JAMES C. Wang,et al.  Cellular roles of DNA topoisomerases: a molecular perspective , 2002, Nature Reviews Molecular Cell Biology.

[6]  V. Stella,et al.  A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. , 1992, Journal of pharmaceutical sciences.

[7]  H. Strutt,et al.  Camptothecin cytotoxicity in mammalian cells is associated with the induction of persistent double strand breaks in replicating DNA. , 1991, Nucleic acids research.

[8]  R. D. Hunter,et al.  WHO Handbook for Reporting Results of Cancer Treatment , 1980 .

[9]  L. L. Jung,et al.  Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: can we improve it? , 2001, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[10]  T. Burke,et al.  The important role of albumin in determining the relative human blood stabilities of the camptothecin anticancer drugs. , 1995, Journal of pharmaceutical sciences.

[11]  Y. Pommier,et al.  Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. , 1998, Biochimica et biophysica acta.

[12]  H. Zhao,et al.  20-O-acylcamptothecin derivatives: evidence for lactone stabilization. , 2000, The Journal of organic chemistry.

[13]  H. Rosing,et al.  A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin , 2002, British Journal of Cancer.

[14]  L. Liu,et al.  Interaction between replication forks and topoisomerase I-DNA cleavable complexes: studies in a cell-free SV40 DNA replication system. , 1993, Cancer research.

[15]  A. Tolcher,et al.  A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Y. Pommier,et al.  Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen. , 1995, Cancer research.

[17]  H. Fiebig,et al.  Design and optimization of 20-O-linked camptothecin glycoconjugates as anticancer agents. , 2001, Journal of medicinal chemistry.

[18]  L. Liu,et al.  Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. , 1989, Cancer research.

[19]  Dae-Kee Kim,et al.  Recent advances in topoisomerase I-targeting agents, camptothecin analogues. , 2002, Mini reviews in medicinal chemistry.

[20]  R. Sternglanz,et al.  Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. , 1988, Molecular pharmacology.

[21]  L. Seymour.  Passive tumor targeting of soluble macromolecules and drug conjugates. , 1992, Critical reviews in therapeutic drug carrier systems.

[22]  Leroy F. Liu,et al.  Mechanism of Action of Camptothecin , 1996, Annals of the New York Academy of Sciences.

[23]  FDA approves irinotecan as first-line therapy for colorectal cancer. , 2000, Oncology.

[24]  C. Bailly.  Topoisomerase I poisons and suppressors as anticancer drugs. , 2000, Current medicinal chemistry.

[25]  T. Burke.  Chemistry of the camptothecins in the bloodstream. Drug stabilization and optimization of activity. , 1996, Annals of the New York Academy of Sciences.

[26]  P. Rougier,et al.  CPT-11 in the treatment of colorectal cancer: clinical efficacy and safety profile. , 1996, Seminars in oncology.

[27]  U. Vanhoefer,et al.  Irinotecan in the treatment of colorectal cancer: clinical overview. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  P. D'Arpa,et al.  Ubiquitin-dependent Destruction of Topoisomerase I Is Stimulated by the Antitumor Drug Camptothecin* , 1997, The Journal of Biological Chemistry.

[29]  C. Conover,et al.  Camptothecin delivery systems: enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker , 1998, Cancer Chemotherapy and Pharmacology.

[30]  Y. Pommier,et al.  Conversion of Topoisomerase I Cleavage Complexes on the Leading Strand of Ribosomal DNA into 5′-Phosphorylated DNA Double-Strand Breaks by Replication Runoff , 2000, Molecular and Cellular Biology.

[31]  K. Kohn,et al.  Correlations between S and G2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells. , 1996, Cancer research.

[32]  H. Hansen,et al.  Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. , 1972, Cancer chemotherapy reports.

[33]  T. Burke,et al.  Chemistry of the Camptothecins in the Bloodstream , 1996 .

[34]  R J Reitemeier,et al.  Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. , 1972, Cancer chemotherapy reports.

[35]  S. Arbuck,et al.  Clinical status and optimal use of topotecan. , 1997, Oncology.

[36]  Peter W Swaan,et al.  Camptothecins , 2012, Drugs.

[37]  S. Hecht,et al.  Role of the 20-hydroxyl group in camptothecin binding by the topoisomerase I-DNA binary complex. , 1999, Biochemistry.

[38]  W. Mcguire.  CLINICAL STATUS AND OPTIMAL USE OF TOPOTECAN , 1997 .